Consult with me on Maven
March 2014
- Circassia raises $332M in London IPO (CIR.L) 
- Vectura (VEC.L) acquiring Activaero, raises GBP200M in placing.
- Venrock plans $200M fund.
- Tesaro (TSRO) and AnaptysBio team up on cancer immunotherapies for $125M
- Charles River to acquire Galapagos (GLPG.BR) service divisions 

News, June 19, 2013

- bluebird bio raises $101M in upsized IPO. Opens at $25.50 (BLUE).
- Prosensa amends IPO and sets price range (RNA).
- FDA to review BLA from Pharming/Santarus. 
- Exact Sciences raises $67.9M in follow-on.
- Royalty Pharma ends hostile bid for Elan. 
- AstraZeneca and NGM Pharma sign deal to develop diabetes drugs.

News, Feb 8, 2013.

- Pozen presents positive Phase III data at stroke conference. 
- GSK files MAA with EMA for trametinib as monotherapy and in combo with dabrafenib for metastatic melanoma.
- Addex Therapeutics to refocus pipeline, structure Geneva operations.
- Germany's Federal Joint Committee says Vertex's Kalydeco provides significant benefit.
- Acceleron's eight Phase II trials.
- Lilly discontinues tabalumab for rheumatoid arthritis.
- €196 M pan-European drug discovery platform launched.
- Elan, Biogen Idec ink $3.25 B deal for MS drug Tysabri.

News, Jan 31, 2013 

- Celsion Phase III HEAT study fails. 
- FDA to hold a public hearing on ALS on Feb 25.
- Genzyme/ISIS' Kinamro to be priced at $176,000/year. 
- Pharmaxis' Bronchitol gets negative vote from FDA advisory committee.
- VC Edmond de Rothschild to raise $500 M over four years.
- Antibody company KaloBios preparing for IPO. 
- Stemline jumps 18% on its first day of trading. 

News, Oct 3 2012 .

- Sarepta presents 48 week data in Duchenne Muscular Dystrophy.
- Arqule drops 55% on Phase III MARQUEE trial discontinuation.
- Sanofi Gaucher's therapy meets Phase III endpoints.
 - J&J and Astellas strike a deal for JAK inhibitor RA drug.
- Merck Serono spins out newco to develop AD assets.
- US Dept. of Defense to continue funding Tekmira's Ebola program.
- Ablynx and Merck in Nanobodies deal for up to $590M.
- Antabio closes seed round of crowdfunding: €300k /200 investors.

News, July 20 2012.

- Durata raises $67.5M in IPO .
- Actelion up 5.7% after raising guidance.
- BB Biotech aims for 10% annual return.
- Stemline Therapeutics sets IPO range, to raise a maximum of $50M
- Genzyme-marketed test sees positive results.
- EMA to publish meetings agendas and minutes.

Transition to Chimera Research Group.

I'm excited to join a team of superb professional biopharma analysts as a contributor for the next year. My analyses and brief notes on selected stocks will be published there from now on. Subscribe to Chimera Research Group here